Some view the COVID-19 pandemic as a reputational turning point for pharma and an opportunity to solidify a more positive impact on society. Many pharmaceutical companies are furthering this goal by incorporating ESG into their operations.
The United States continues to face a growing obesity epidemic. The number of people living with excess weight has tripled since 1975, standing at 39% of the American population. Carrying extra pounds is linked with lifelong illnesses such as cardiovascular disease, diabetes, and cancer.